Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

IMPORTANCE: Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monotherapies or in combination with anti–cytotoxic T-lymphocyte–associated antigen 4 have shown clinical activity in patients with metastatic non–small cell lung cancer. OBJECTIVE: To compare durvalumab, wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizvi, Naiyer A., Cho, Byoung Chul, Reinmuth, Niels, Lee, Ki Hyeong, Luft, Alexander, Ahn, Myung-Ju, van den Heuvel, Michel M., Cobo, Manuel, Vicente, David, Smolin, Alexey, Moiseyenko, Vladimir, Antonia, Scott J., Le Moulec, Sylvestre, Robinet, Gilles, Natale, Ronald, Schneider, Jeffrey, Shepherd, Frances A., Geater, Sarayut Lucien, Garon, Edward B., Kim, Edward S., Goldberg, Sarah B., Nakagawa, Kazuhiko, Raja, Rajiv, Higgs, Brandon W., Boothman, Anne-Marie, Zhao, Luping, Scheuring, Urban, Stockman, Paul K., Chand, Vikram K., Peters, Solange
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146551/
https://www.ncbi.nlm.nih.gov/pubmed/32271377
http://dx.doi.org/10.1001/jamaoncol.2020.0237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146551/
https://www.ncbi.nlm.nih.gov/pubmed/32271377
http://dx.doi.org/10.1001/jamaoncol.2020.0237

Ejemplares similares